Navigation Links
Marinus Pharmaceuticals Adds Two Life Sciences Veterans to its Board of Directors
Date:7/29/2009

BRANFORD, Conn., July 29 /PRNewswire/ -- Marinus Pharmaceuticals, Inc. a developer of drugs to treat serious neurological and psychiatric disorders, today announced the appointment of George F. Horner III of Sofinnova Ventures and Harry T. Rein of Foundation Medical Partners to its Board of Directors.

"We are thrilled to expand our board of directors with George and Harry, both of whom have tremendous track records for advancing drug pipelines, leading pharmaceutical and life sciences companies and in delivering value to stakeholders," said John Krayacich, CEO , president and director of Marinus Pharmaceuticals. "Their expertise will be extremely valuable as we progress our lead product, ganaxolone for epilepsy, through additional clinical trials."

George F. Horner III is a pharmaceutical/biopharmaceutical executive with over 40 years of experience in the industry. Currently, Mr. Horner is an executive-in-residence with Sofinnova Ventures, a leading venture capital firm. Previously, he was CEO of Prestwick Pharmaceuticals, a CNS company that he directed to obtain FDA approval for Tetrabenazine (TBZ), the first drug ever licensed in the United States to treat Huntington's Disease patients. Prior to that, Mr. Horner was CEO of Vicuron Pharmaceuticals, an anti-infective company that he grew from a market value of $12.8 million to a company sold to Pfizer for $1.9 billion. Additionally, he has held numerous executive, general management, business development and marketing/sales positions with Abbott Laboratories and E.R. Squibb across 4 continents, worldwide. Mr. Horner is Chairman of the Board of Creabilis Therapeutics of Luxembourg and a member of the board of Novexel, SA, France.

"I look forward to working with the Marinus team and am impressed by the financing and clinical milestones the company accomplished recently," said Mr. Horner. "I'm especially eager to be a part of a compan
'/>"/>

SOURCE Marinus Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Marinus Pharmaceuticals Appoints John Krayacich as President and Chief Executive Officer
2. Marinus Pharmaceuticals Raises $20 Million in Series B Financing
3. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
4. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
7. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
8. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
9. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
10. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
11. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 2014  United Therapeutics Corporation (NASDAQ: ... MDT ) has submitted a pre-market ... Administration (FDA) for the use of Medtronic,s SynchroMed ... a newly developed catheter) for use with United ... to patients with pulmonary arterial hypertension.   ...
(Date:12/24/2014)... , Dec. 24, 2014   BioLife Solutions , ... manufacturer and marketer of proprietary clinical grade hypothermic ... precision thermal shipping products for cells and ... will hold its 2015 Annual Meeting of Stockholders on ... the expected date for the Annual Meeting represents a ...
(Date:12/24/2014)... 2014 Earlier this year in a ... director of the Adult Stem Cell Technology Center, LLC ... and under appreciated unique property of adult tissue stem ... Cells: Misunderstood in the Past, Important for the Future,” ... He gave the address at the 4th World ...
(Date:12/24/2014)... According to Ross Selinger, President of ... Global, the national office market continues to be strong, driven ... evidenced by the third quarter’s surprising 3.9% GDP, unemployment decreasing ... costs have held inflation down and the Fed is keeping ... market remaining soft. , This solid economic news is having ...
Breaking Biology Technology:United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4BioLife Solutions Sets Date for Annual Meeting of Stockholders 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4ITRA Global Reports Long Island Is Out of Sync With The National Office Market 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 3
... SOUTH SAN FRANCISCO, Calif., Jan. 12 Sunesis Pharmaceuticals, ... clinical update on voreloxin, its novel investigational drug candidate ... myeloid leukemia (AML) and ovarian cancer. The clinical ... Annual JP Morgan Healthcare Conference in San Francisco. "2008 ...
... Calif., Jan. 12 MAP,Pharmaceuticals, Inc. (Nasdaq: ... 3 clinical programs, Unit Dose Budesonide (UDB) for children,with ... For UDB, all,patients have completed the 12 week ... for MAP0004, the company currently expects to complete,enrollment in ...
... Calif., Jan. 12 Anacor Pharmaceuticals today,announced that it ... million from its collaboration partner, GlaxoSmithKline. Anacor may,receive ... to clinical development and commercial sales. , ... we have made as a result of,the alliance we ...
Cached Biology Technology:Sunesis Pharmaceuticals Provides Year-End Clinical Update on Voreloxin 2Sunesis Pharmaceuticals Provides Year-End Clinical Update on Voreloxin 3Sunesis Pharmaceuticals Provides Year-End Clinical Update on Voreloxin 4Sunesis Pharmaceuticals Provides Year-End Clinical Update on Voreloxin 5Sunesis Pharmaceuticals Provides Year-End Clinical Update on Voreloxin 6MAP Pharmaceuticals Provides Update on Progress of Two Phase 3 Clinical Programs 2MAP Pharmaceuticals Provides Update on Progress of Two Phase 3 Clinical Programs 3Anacor Achieves Milestone from GSK for Boron-Based Systemic Antibacterial Product Candidate 2
(Date:12/19/2014)... 2014   LaunchKey , the first decentralized mobile ... Internet of Things era, today announced the close of ... was led by Metamorphic Ventures with participation from ENIAC ... and others.  LaunchKey has raised $4 million to date, ... team and bring LaunchKey to market in 2015. ...
(Date:12/17/2014)... 16, 2014 Valencell, a leader in performance ... technology to industry leaders such as Intel, Jabra, Atlas, ... biometric wearable products. These products will be showcased at ... Las Vegas . "Our partners ... and robust – with the clinical data to back ...
(Date:12/11/2014)... , Dec. 09, 2014 Research and ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has ... in the APAC Region 2015-2019"  report to their ... in this market is advances in technology. With ... upgrade biometric solutions to the latest standard that ...
Breaking Biology News(10 mins):LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... reserves of methane gas seeping from the melting Arctic ice ... knew: As the permafrost thaws, there is a release of ... The trick was figuring out how much, said Chanton, the ... The four-member team whose findings were published in ...
... rooms finds television remotes to be among the most ... carry the potential to cross-contaminate rooms. Researchers from ... the 2012 General Meeting of the American Society for ... guests with a safe and secure environment. Currently, ...
... In Israel,s Negev Desert, a plant called sweet mignonette or ... the spiny mouse spit out the plant,s seeds when eating ... into a seed spreader that helps the plant reproduce, says ... fascinating that these little mice are doing analytical chemistry, assaying ...
Cached Biology News:Study: Seeking Arctic methane has serious implications for Florida coastline 2The most contaminated surfaces in hotel rooms 2Ptooey! 2Ptooey! 3Ptooey! 4
...
These 22x40mm rectangular No.1 Corning cover glasses are made from No. 0211 zinc titania glass and are 0.16 to 0.19mm thick. • Approx. Pcs Oz : 73...
...
... self-contained work area that will help protect ... bulbs irradiate the work area prior to ... will be amplified. Containment features reduce the ... has acrylic windows for a clear view, ...
Biology Products: